GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.
More about the company